Neuroleptic malignant syndrome versus malignant disease: idiosyncratic or synchronous?
Shintani
Futoshi
F
Department of Psychiatry, Tokyo Musashino Hospital, Tokyo, 173-0037 Japan. f-shintani@tmh.or.jp
Izumi
Masaki
M
Fujimura
Naohiro
N
D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D000928:Antidepressive Agents / Q000009:adverse effects; D018692:Antimanic Agents / Q000009:adverse effects; D001005:Anus Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy; D015984:Causality; D003113:Colonoscopy; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005334:Fever / Q000209:etiology; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000150:complications / Q000175:diagnosis*; D014057:Tomography, X-Ray Computed
D000928:Antidepressive Agents; D018692:Antimanic Agents; D016651:Lithium Carbonate; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form